Replies to post #149067 on Biotech Values

[DewDiligence]

Prevnar 13 immune response in adults age <50 looks ok:

http://www.reuters.com/article/2012/10/04/pfizer-study-idUSL3E8L45JE20121004

Pfizer said Prevnar 13 met the main goal of the late-stage study by showing that the immune response to the vaccine in the 18- to 49-year-old age group was not inferior when compared with the response in the 60-to 64-year-old group.

…the favorable results from the study will support both its recent European Union application to market the product for that 18-49 age group, as well as applications it plans to make in other countries.

So, we know Prevnar 13 creates a robust immune response in all groups of patients tested. However, whether Prevnar 13 becomes a blockbuster drug for adults depends on the outcomes study in progress.